|
E.V. Biryukova
FIXED-DOSE COMBINATIONS IN THE THERAPY OF TYPE 2 DIABETES MELLITUS: THE WAY TO ACHIEVING GOOD GLYCEMIC CONTROL
|
6-12 |
|
M.B. Antsiferov (1), Zh.E. Belaya (2)
INCREASING THE DOSE OF SOMATOSTATIN ANALOGUES OF IN PATIENTS WITH ACTIVE FORM OF ACROMEGALY: LITERATURE REVIEW AND PROSPECTS FOR APPLICATION
|
13-16 |
|
A.F. Verbovoy (1), I.A. Tsanava (1), N.I. Verbovaya (1), R.A. Galkin (1), I.V. Madyanov (2)
POLYMORBIDITY AND MODERN MEDICINE
|
17-20 |
|
E.Yu. Komelyagina, M.B. Antsiferov
DIABETIC DISTAL POLYNEUROPATHY: THE PRINCIPLES OF DIAGNOSTICS AND THERAPY
|
21-25 |
|
M.B. Antsiferov
THE USE OF INSULIN GLARGINE 300 IU/ML (TOUJEO SOLOSTAR®) IN REAL CLINICAL PRACTICE
|
26-30 |
|
M.B. Antsiferov
EFFECT OF SGLT-2 INHIBITORS ON CARDIOVASCULAR OUTCOMES: REVIEW OF RESULTS OF CVD-REAL TRIAL
|
31-37 |
|
O.S. Elsukova, A.A. Sobolev
ADVANTAGES OF SWITCH TO PREMIXED INSULIN DEGLUDEC/ ASPART IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED AN OPTIMAL CONTROL WITH PREVIOUS INSULIN THERAPY
|
38-44 |
|
I.G. Tsvetkova (1), A.N. Kaukova (2), N.A. Belyakova (1), O.A. Vasyutkova (2), O.V. Konovalova (2), A.V. Lareva (1)
DISTURBANCES OF THE AUTONOMIC INNERVATION OF THE CARDIOVASCULAR SYSTEM AND HEMOSTASIS: THEIR ROLE IN THE CHANGE OF MICROCIRCULATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
46-50 |
|
L.N. Eliseyeva, A.Yu. Blednova, I.S. Kulabukhova, M.Sh. Khuako, M.I. Bocharnikova
EFFECTIVENESS OF ADDITIONAL CARDIOTROPIC THERAPY IN PATIENTS WITH SYMPTOMS OF HYPERTHEROSIS ON THE BACKGROUND OF DIFFUSE TOXIC GOITER
|
51-57 |
|
A.Yu. Chikanova (1), L.Yu. Khamnuyeva (1, 2), O.G. Karnoukhova (1), N.S. Sudakova (1), N.P. Tokareva (2)
FEATURES OF URINE MICROFLORA IN DIABETIC PATIENTS
|
58-61 |
|
A.F.Verbovoy, L.A. Sharonova, S.A. Burakshayev, E.V. Kotelnikova, T.V. Smirnova
OPPORTUNITIES FOR PREVENTION OF CHANGES IN SKIN AND ORAL MUCOSA IN DIABETES MELLITUS AT THE PRESENT STAGE
|
62-65 |
|
E.V. Biryukova (1), N.M. Platonova (2)
AMIODARONE THERAPY AND THYROID FUNCTION
|
66-71 |
Русский
